Description
The purpose of the ongoing THRIVE Clinical Program is to measure the effect of CTP-543 on
hair regrowth and to evaluate safety in people with alopecia areata. The THRIVE Clinical
Program is now enrolling adults 18 to 65 years old with at least 50% scalp hair loss due to
alopecia areata.
The current episode of hair loss must have lasted at least 6 months and no longer
than 10 years. The total time a person has had alopecia areata may exceed 10 years. Following a
24-week treatment period, participants will have the opportunity to enroll into an open-label
extension study in which all participants will receive an active dose of CTP-543.
Please contact our office in Brighton for more information.
Discussion
By posting you agree to the Terms and Privacy Policy.